Background:The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody(ANCA)-associated vasculitis.Methods:In this randomized,controlled trial,we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering schedule.All the patients received either cyclophosphamide(followed by azathioprine)or rituximab.
展开▼